AB Science AB.PA · EUR

Its shares trade on Euronext Paris under the ticker AB.PA. It has been listed since 21 April 2010. In the fiscal year to 31 December 2025, it reported revenue of €1.2m and a net loss of €1.6m. At that date it held total assets of €24.5m and shareholders' equity of −€17.2m.

AB Science SA engages in the research, development, and sales of protein kinase inhibitor drugs. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2010-04-21. The company is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine. The main focus of the Company is the development of tyrosine kinase inhibitors, for instance Masitinib which is a tyrosine kinase inhibitor used as a veterinary medicine in the treatment of canine mast cell tumors. The firm is present in the United States and Europe. As of December 31, 2013, the Company operated though a subsidiary, AB Science USA LCC, based in the United States.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Alain MoussyChairman of the Board, Chief Executive Officer, since 2001€495,000
• Mr. Denis GicquelDeputy Chief Executive Officer€41,000
• Mr. Laurent GuyChief Financial Officer
• Mr. Patrick MoussyDirector
• Ms. Cecile de GuillebonIndependent Director
• Ms. Catherine Johnston-RoussilloIndependent Director
• Ms. Guillemette LatschaIndependent Director
• Mr. Renaud SassiIndependent Director

Overall

29

Environment

33

Social

15

Governance

38

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.